Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone

References

• Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1051–1067.
   PubMed Web of Science ®Google Scholar
• Chen X, Wei QQ, Chen Y, et al. Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):53–60.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Zhang M, Quiroz Zarate A, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012 Sep;259(9):1923–1928.
   PubMed Web of Science ®Google Scholar
• Keizman D, Ish-Shalom M, Berliner S, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci. 2009 Oct 15;285(1-2):95–99.
   PubMed Web of Science ®Google Scholar
• Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014 Jun;261(6):1133–1138.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hirayama T, Takazawa T, et al. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51(12):1501–1508.
   PubMed Web of Science ®Google Scholar
• Oh SI, Baek S, Park JS, et al. Prognostic role of serum levels of uric acid in amyotrophic lateral sclerosis. J Clin Neurol. 2015 Oct;11(4):376–382.
   PubMed Web of Science ®Google Scholar
• O’Reilly ÉJ, Liu D, Johns DR, et al. Serum urate at trial entry and ALS progression in EMPOWER. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2017 2017/01/02;18(1-2):120–125.
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Edaravone: A new drug approved for ALS. Cell. 2017 Nov 2;171(4):725.
   PubMed Web of Science ®Google Scholar
• Fujisawa A, Yamamoto Y. Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. Redox Rep. 2016 May;21(3):98–103.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y. Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite. J Clin Biochem Nutr. 2017 Jan;60(1):49–54.
   PubMed Web of Science ®Google Scholar
• Ohta Y, Yamashita T, Nomura E, et al. Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients. J Neurol Sci. 2020 Aug 15;415:116906.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293–299.
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610–617.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999 Oct 31;169(1-2):13–21.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Yamazaki K, et al. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1999 Jul;46(1):129–131.
   PubMed Web of Science ®Google Scholar
• Smith RG, Henry YK, Mattson MP, et al. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1998 Oct;44(4):696–699.
   PubMed Web of Science ®Google Scholar
• Ihara Y, Nobukuni K, Takata H, et al. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res. 2005 Jan;27(1):105–108.
   PubMed Web of Science ®Google Scholar
• Ikawa M, Okazawa H, Tsujikawa T, et al. Increased oxidative stress is related to disease severity in the ALS motor cortex: A PET study. Neurology. 2015 May 19;84(20):2033–2039.
   PubMed Web of Science ®Google Scholar
• Nikolic-Kokic A, Stevic Z, Blagojevic D, et al. Alterations in anti-oxidative defence enzymes in erythrocytes from sporadic amyotrophic lateral sclerosis (SALS) and familial ALS patients. Clin Chem Lab Med. 2006;44(5):589–593.
   PubMed Web of Science ®Google Scholar
• Cova E, Bongioanni P, Cereda C, et al. Time course of oxidant markers and antioxidant defenses in subgroups of amyotrophic lateral sclerosis patients. Neurochem Int. 2010 Apr;56(5):687–693.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhang Q, Ke Y, et al. Serum uric acid levels in patients with amyotrophic lateral sclerosis: a meta-analysis. Sci Rep. 2018 Jan 18;8(1):1100.
   PubMedGoogle Scholar
• Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006 Dec;7(4):241–245.
   PubMed Web of Science ®Google Scholar
• Nagase M, Yamamoto Y, Miyazaki Y, et al. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016 May;21(3):104–112.
   PubMed Web of Science ®Google Scholar
• Boillée S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006 Oct 5;52(1):39–59.
   PubMed Web of Science ®Google Scholar
• Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017 Jul;16(7):505–512.
   PubMed Web of Science ®Google Scholar
• Shefner J, Heiman-Patterson T, Pioro EP, et al. Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of study 19 (MCI186-19). Muscle Nerve. 2020 Feb;61(2):218–221.
   PubMed Web of Science ®Google Scholar
• Chiò A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):310–323.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ogata S, Tanaka H, et al. The relationship between body mass index and uric acid: a study on Japanese adult twins. Environ Health Prev Med. 2015 Sep;20(5):347–353.
   PubMed Web of Science ®Google Scholar
• Yao X, Chen L, Xu H, et al. The association between serum uric acid and bone mineral density in older adults. Int J Endocrinol. 2020;2020:3082318.
   PubMed Web of Science ®Google Scholar